





MONDAYS WITH MARK & MICHAEL

Monday, November 17, 2025 | 1:00 – 2:00 PM

TOPIC #56

The State of Diabetes in the U.S.: Emerging Treatments and Employer Strategies

Featured Speaker:



Leon Igel, MD, FACP, FTOS, DABOM Chief Medical Officer FlyteHealth





THE STATE OF DIABETES IN THE U.S. Prevalence, Economic Impact & Employer Strategies

Leon Igel, MD, FACP, FTOS, DABOM Chief Medical Officer, FlyteHealth





Diabetes in the U.S. -- Prevalence & Trends

- 38 million people in the US have diabetes (11.6% of the population);
 1 in 5 are undiagnosed
- 98 million adults have prediabetes; >80% are unaware
- Often coincides with Obesity (>40% of the population)

Demographics:

- Rising rate of early-onset T2DM
- Highest prevalence in adults ≥ age 65 (~29%)
- Marked disparities across race/ethnicity and socioeconomic status
- Many cases detected late in the disease course





Economic Burden & Workforce Impact

Total annual cost of diabetes in U.S. (2022):
 \$413B (\$307B direct medical, \$106B indirect)

Employer impact:

- Higher rates of absenteeism, presenteeism, short-term disability
- Increased cardiometabolic claims (CVD, CKD) and pharmacy spend
- Trajectory without intervention:
 - Rising spend driven by complications & hospitalizations





Why Employers Must Act Now

- Earlier detection prevents complications and lowers total cost of care
- Evidence-based prevention (DPP) and medical therapy avert progression from prediabetes to T2DM
- High-value coverage decisions (GLP-1s, SGLT2s, CGM, virtual care) improve outcomes when paired with guardrails







Upcoming NEBGH events:

- November 20 The Silent Crisis: Rethinking Men's Health at Work
- December 1 Mondays with Dr. Mark & Dr. Michael
- December 10 Annual Membership Meeting

SAVE THE DATE FOR THESE 2026 IN-PERSON EVENTS!

- February 12 31st Annual Tribute to Leadership
- March TBA Cardiometabolic Health as a Business Imperative
- June 18 15th Annual Health & Wellness Benefits Conference



